Navigation Links
Rigel Announces Second Quarter 2011 Financial Results
Date:8/2/2011

sed compensation expense decreased from approximately $3.7 million in the second quarter of 2010 to approximately $3.2 million in the second quarter of 2011.

For the six months ended June 30, 2011, Rigel reported a net loss of $42.3 million, or $0.76 per basic and diluted share, compared to a net income of $4.7 million, or $0.09 per basic and diluted share, for the same period of 2010.

As of June 30, 2011, Rigel had cash, cash equivalents and available-for-sale securities of $279.1 million, compared to $177.3 million as of December 31, 2010.  In June 2011, Rigel completed a public offering in which it sold 18,745,000 shares of common stock at a public offering price of $8.00 per share pursuant to an effective registration statement. The aggregate net proceeds of the offering were approximately $140.5 million after deducting underwriting discounts and commissions and offering expenses. Rigel expects to end 2011 with more than $245.0 million in cash, cash equivalents and available-for-sale securities, which is expected to be sufficient to fund operations into 2014.

"The recent combination of reacquiring R343 and completing our successful financing has had a very positive impact on our pipeline and balance sheet," said James M. Gower, chairman and chief executive officer of Rigel. "We are focused on designing an appropriate Phase 2 clinical study program for R343 in asthma, while continuing to develop our clinical programs in transplant rejection and discoid lupus," he added.Fostamatinib UpdateAZ recently reported that their Phase 3 clinical development program (OSKIRA) to investigate fostamatinib as a treatment for rheumatoid arthritis is progressing well.  AZ expects the first set of data in the second half of 2012 and expects to remain on track to meet the planned US and European new drug application (NDA) filing dates in 2013.  AZ also announced that in the first quarter of 2011 they had commenced a Phase 2b clinical trial (OSK
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Rigel Earns Milestone Payments From AstraZeneca
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2014)... Synedgen announced today the award ... Phase I contract from the National Cancer Institute ... to demonstrate proof-of-concept activity of Synedgen’s proprietary treatment ... tissue damage to the lining of the gastrointestinal ... award, Synedgen will complete efficacy studies for its ...
(Date:9/26/2014)... China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... 2014 annual general meeting of shareholders at its Hong ... Garden Road, Central, Hong Kong , at 9:00 ... Eastern Time on December 11, 2014). Shareholders of record ...
(Date:9/26/2014)... Molecular Biology deals with the ... regulation of cellular activity and its behaviour. It emphasise ... with its environment within the genome. Knowledge on molecular ... therapeutic methodologies for the diagnosis, prognosis and the treatment ... Dr. Srinubabu Gedela, MD of OMICS Publishing Group ...
(Date:9/26/2014)... “Inflamax’s Clinical Data Management group is a SCDM ... allows us to support our group in maintaining the ... Director of Data Management at Inflamax. “Being an ... Clinical Data Managers have been certified by passing the ... offering only the best services to our clients, by ...
Breaking Biology Technology:Synedgen Awarded National Cancer Institute Funding for Promising New Treatment for Medical Radiation-induced Bowel Injury 2China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 11, 2014 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 3
... N.Y., Nov. 5 BioSpecifics Technologies Corp. (Nasdaq: ... today announced its financial results for the third quarter ... happy that, in September of this year, the FDA,s ... 12-0, the approval of XIAFLEX(TM) for the treatment of ...
... November 5, 2009 Senomyx, Inc. (Nasdaq: SNMX ), ... discover novel flavor ingredients for the food, beverage, and ingredient ... results for the third quarter ended September 30, 2009. ... compared to $4.0 million for the third quarter of 2008, ...
... PLYMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... the Company plans to release third quarter 2009 financial results ... The Company will hold a conference call ... quarter 2009 results. Listeners may access the call by,dialing ...
Cached Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BMP Sunstone to Report Third Quarter 2009 Financial Results 2
(Date:9/29/2014)... Juan Manuel Santos has presented Dr. Cristin Samper, ... with the prestigious Order of San Carlos. , ... foreign civilians and military officers who have made ... field of international relations. , An international authority ... was invited to the Colombian Residence in New ...
(Date:9/29/2014)... Va.September 29, 2014Research!America,s 19th annual Advocacy Awards ... who are trailblazers in advancing medical progress to ... nation. The event will take place on Wednesday, ... Auditorium in Washington, DC. , The 2015 Advocacy ... Robin Roberts; Michael Milken, founder of the Milken ...
(Date:9/29/2014)... 29, 2014 Growing Demand ... with Increasing Security Concerns Continue to Propel Biometrics ... is one of the fastest growing ... biometrics systems, majorly in various government projects such ... modality based biometrics dominates the country,s biometrics market, ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... Bar Harbor, Maine - Currently, 5-8% of the ... ( www.niaid.nih.gov ). Many of these are chronic ... aggregate within a single family, suggesting they are ... To help researchers investigate these common pathways, ...
... UT Southwestern Medical Center have eliminated non-small cell lung ... called BEZ235 in combination with low-dose radiation. In ... Cancer Research , UT Southwestern researchers found that if ... tumor cells with otherwise nontoxic radiation, the drug blocked ...
... are reporting results of one of the first studies ... anti-odor, anti-bacterial socks now on the market. Their findings, ... Environmental Science & Technology , may suggest ways ... these particles to the environment, where they could harm ...
Cached Biology News:UT Southwestern researchers use drug-radiation combo to eradicate lung cancer 2
... DNA120OP is specifically engineered for efficient drying ... incorporates a glass cover and a post-trap ... unattended, odor-free processing of samples in ammonium ... Synthetic Oligos , ...
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... The DNA120 is a dedicated concentrator for ... precipitates of DNA/RNA. The integrated system combines ... pump. The compact design, automatic pump and ... run time; one for heater time), makes ...
... 1 Block MBS Start up kit. Includes ... and choice of 1 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
Biology Products: